Skip to main content

Table 3 Results for CRP-positive and CRP-negative patients

From: Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers

 

CRP-positive patients

CRP-negative patients

 

Baseline value

Adjusted mean changes (95% CI)

P-value

Baseline value

Adjusted mean changes (95% CI)

P-value

  

<4 years

≥4 years

  

<4 years

≥4 years

 
  

n = 30

n = 15

  

n = 26

n = 37

 

BASDAI

5.4

3.3 (2.7, 4.0)

2.4 (1.5, 3.3)

0.11

5.5

3 (2.3, 3.7)

1.3 (0.7, 1.9)

0.001

BASFI

4.2

2.4 (1.8, 3.0)

1.8 (0.9, 2.7)

0.23

4.5

2.4 (1.8, 3.1)

0.9 (0.4, 1.5)

0.001

BASMI

1.5

0.1 (−0.3, 0.4)

0.4 (−0.1, 0.9)

0.30

2.0

0.5 (0, 1)

−0.3 (−0.6, 0.1)

0.01

ASDAS

3.6

1.9 (1.6, 2.2)

1.5 (1.1, 1.9)

0.07

2.8

1.3 (1, 1.6)

0.6 (0.3, 0.8)

0.001

CRP*

13.8

2.7 (2.2, 3.3)

2.1 (1.5, 3)

0.20

3.6

1.2 (1, 1.5)

1.2 (1, 1.4)

0.86

MRI SIJ

6.6

4.6 (3.6, 5.7)

3.5 (2, 4.9)

0.19

3.8

2.5 (1.8, 3.2)

2.5 (1.9, 3.1)

0.96

  1. *Log-transformed CRP results were back-transformed; P-value <0.05 was taken to indicate statistically significant differences between two groups; adjusted mean changes from baseline under treatment with etanercept or adalimumab (95% CI). Outcome differences were adjusted for baseline status (see Methods). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, magnetic resonance imaging; SIJ, sacroiliac joint.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us